Starpharma Holdings (ASX:SPL) Debt-to-Equity : 0.13 (As of Jun. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Starpharma Holdings Debt-to-Equity?

Starpharma Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$1.57 Mil. Starpharma Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$1.96 Mil. Starpharma Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2024 was A$28.12 Mil. Starpharma Holdings's debt to equity for the quarter that ended in Jun. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Starpharma Holdings's Debt-to-Equity or its related term are showing as below:

ASX:SPL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.24
Current: 0.13

During the past 13 years, the highest Debt-to-Equity Ratio of Starpharma Holdings was 0.24. The lowest was 0.00. And the median was 0.02.

ASX:SPL's Debt-to-Equity is ranked better than
52.67% of 1029 companies
in the Biotechnology industry
Industry Median: 0.15 vs ASX:SPL: 0.13

Starpharma Holdings Debt-to-Equity Historical Data

The historical data trend for Starpharma Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Debt-to-Equity Chart

Starpharma Holdings Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.02

0.17

0.24

0.13

Starpharma Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.17	0.19	0.24	0.09	0.13

Competitive Comparison of Starpharma Holdings's Debt-to-Equity

For the Biotechnology subindustry, Starpharma Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starpharma Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's Debt-to-Equity falls into.

Starpharma Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Starpharma Holdings's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.571	+	1.957)	/	28.116
	=	0.13

Starpharma Holdings's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.571	+	1.957)	/	28.116
	=	0.13

Starpharma Holdings (ASX:SPL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Starpharma Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Starpharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SPHRY:USA SPHRF:USA PQ6:Germany

Address

4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067

Website

https://www.starpharma.com

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings Headlines

No Headlines